Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma

Stage IV Esophageal Squamous Cell Carcinoma Clinical Trial

Official title:
Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma

Status Withdrawn

Clinical Trial Summary

There have been reports suggesting that anti-epidermal growth factor antibody nimotuzumab is advantageous for advanced esophageal cancer patients in combination with chemotherapy or radiotherapy. However, whether maintenance therapy of nimotuzumab provides benefit to advanced esophageal cancer patients is not known.

Clinical Trial Description

We design this clinical trial to confirm the efficacy of maintenance treatment of nimotuzumab after initial treatment. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Carcinoma
Carcinoma, Squamous Cell
Esophageal Neoplasms
Stage IV Esophageal Squamous Cell Carcinoma

Clinical Trial Details

NCT number	NCT02011594
Study type	Interventional
Source	Zhejiang University
Contact
Status	Withdrawn
Phase	Phase 2
Start date	January 2014
Completion date	February 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01178944` - Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer	Phase 2
Withdrawn	`NCT02034968` - Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma	Phase 2
Recruiting	`NCT04221893` - Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers	N/A